Veru Inc. (VERU) Stock Score, Valuation & Financial Research

Veru Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for VERU

Veru Inc. does not currently have a complete Wall Street Score. The stored market price is USD 2.47. These figures are a research snapshot, not a buy or sell recommendation.

What Veru Inc. does

Veru Inc. operates as a biopharmaceutical firm primarily dedicated to advancing novel therapeutic agents for various types of cancer. Commercially, Veru markets the FC2 internal condom, designed to offer dual protection against both unplanned pregnancies and the transmission of sexually transmitted infections. This product is distributed globally to a diverse clientele, including governmental health departments, UN organizations, non-profit entities, and commercial distributors. Its robust development pipeline features a range of investigational therapies, notably within oncology: Enobosarm, an orally administered selective androgen receptor agonist, is progressing through Phase III clinical trials for treating metastatic breast cancer that is AR+, ER+, and HER2-negative. Sabizabulin is undergoing Phase IIb studies for the same type of metastatic breast cancer. Furthermore, a combination therapy of Enobosarm with abemaciclib is in Phase III for AR+ ER+ HER2- metastatic breast cancer. For metastatic triple-negative breast cancer, Veru is exploring a combination of Sabizabulin (an oral targeted cytoskeleton disruptor) and Enobosarm (a selective androgen receptor agonist) in Phase II trials. The company's portfolio also extends to prostate cancer: Sabizabulin is in Phase II trials for metastatic castration and androgen receptor targeting agent-resistant prostate cancer. VERU-100, a GnRH antagonist peptide delivered via injection, is also in Phase II for advanced hormone-sensitive prostate cancer. Beyond oncology, Veru is investigating other conditions: Zuclomiphene Citrate is in Phase II for managing hot flashes. Sabizabulin has reached Phase III for treating SARS-CoV-2 in high-risk patients susceptible to acute respiratory distress syndrome. Additionally, the firm is developing a novel pharmaceutical formulation aimed at alleviating lower urinary tract symptoms associated with an enlarged prostate in men. Originally established as The Female Health Company in 1971, the corporation adopted the name Veru Inc. in July 2017. Its corporate headquarters are situated in Miami, Florida.

Company business and revenue

Research reporting period: 2025-09-30. A research update is not a new financial filing.

How the company makes money

Veru Inc. is a late clinical stage biopharmaceutical company that focuses on the development of pharmaceutical products for the treatment of cardiometabolic and inflammatory diseases. The company currently generates no revenue from product sales and relies on capital raises, such as public offerings, to fund its ongoing research, clinical development, and operational activities.

Products and services

  • The company is currently focused on the development of pharmaceutical drug candidates, specifically enobosarm for the treatment of obesity and other cardiometabolic diseases.

Suppliers, materials and equipment

  • Contract Manufacturing Organizations — The company utilizes third-party manufacturers to produce its drug candidates, which must comply with FDA current Good Manufacturing Practices (cGMPs). Source

Competitors and product-market comparisons

  • Pharmaceutical and Biotechnology Companies — The company competes with various entities in the biopharmaceutical industry that are developing treatments for obesity and inflammatory diseases. Source

Business strengths to evaluate

  • Focus on late clinical stage development of cardiometabolic and inflammatory disease treatments Source

Business risks and research considerations

  • History of operating losses and dependence on external financing Source
  • Regulatory risks associated with FDA approval and cGMP compliance Source
  • Uncertainty of clinical trial outcomes and development timelines Source

Sources: Company research source

Company research refreshed 2026-10-13. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

VERU financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 2.47
Market capitalization:
39.64M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -13.61M
Free cash flow:
USD -30.04M
Cash:
USD 23.88M
Total debt:
USD 2.68M
EPS:
USD -0.60

What stands out

  • Free cash flow is USD -30.04M, negative for the stored period.
  • The balance sheet shows USD 23.88M of cash versus USD 2.68M of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 21.2M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for VERU

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can VERU fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is VERU likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for VERU to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of VERU's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research VERU

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.